Galidesivir is under clinical development by BioCryst Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Galidesivir’s likelihood of approval (LoA) and phase transition for Yellow Fever took place on 07 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 07 Mar 2022 decreased Galidesivir’s LoA and PTSR for Ebolavirus Infections (Ebola Hemorrhagic Fever), decreased PTSR for Marburgvirus Infections (Marburg Hemorrhagic Fever), and decreased PTSR for Zika Virus Infections.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Galidesivir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Galidesivir overview

Galidesivir (formerly BCX-4430) is under development for the treatment of broad-spectrum antiviral such as yellow fever virus, Ebola and Marburg virus and Zika virus. The drug candidate is administered through the intramuscular and intravenous route of administration. It is an adenosine analogue and RNA dependent-RNA polymerase inhibitor that has broad-spectrum antiviral activity and is developed by using structure-guided drug design method.

It was under development for the treatment of Coronavirus Disease 2019 (COVID-19).

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX9930, BCX9250 and galidesivir (BCX4430). It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.

Quick View Galidesivir LOA Data

Report Segments
  • Innovator
Drug Name
  • Galidesivir
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.